The David Jones Lab: Publications

Print
Print

Szymura SJ, Zaemes JP, Allison DF, Clift SH, D’Innocenzi JM, Gray LG, Mckenna BD, morris BB, Bekiranov S, LeGallo RD, Jones DR, Mayo MW. NF-ĸB upregulates glutamine-fructose-6-phosphate transaminase 2 to promote migration in non-small clell lung cancer. Cell Commun Signal 2019;17(1):24.

Forde PM, Chaft JE, Smith KN, Anagnostou V, TCottrell TR, Hellmann MD, Yang SC, Jones DR, Broderick SR, Battafarano R, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Caushi J, Chan HY, Scharpf RB, White J, Gabrielson E, Zahurak M, Rosner G, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 2018;378:1976-86.

Cottrell TR, Stein JE, Chaft JE, Thompson ED, Rekhtman N, Anagnostou V, Smith KN, Duffield AS, Anders RA, Isbell JM, Jones DR, Cuda JD, Battafarano R, Yang SC, Illei PB, Gabrielson E, Askin F, Velez M, Hellmann MD, Sauter JL, Danilova L, Velculescu VE, Wolchok JD, Topalian SL, Brahmer J, Pardoll DM, Cimino-Matthews A, Forde PM, Taube JM. Histopathologic features of response to neoadjuvant anti-PD-1 in resected non-small cell lung carcinomas (NSCLC):  a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol 2018;29(8):1853-1860.

Bucciarelli PR, Tan KS, Chudgar NP, Brandt W, Montecalvo J, Eguchi T, Liu Y, Travis WD, Adusumilli PS, Jones DR. BRMS1 expression in surgically resected lung adenocarcinoma predicts future metastases and is associated with a poor prognosis. J Thorac Oncol 2018;13:73-84.

Amin EM, Liu Y, Deng S, Chudgar N, Mayo MW, Tan KS, Sanchez-Vega F, Schultz ND, Adusumilli PS, Jones DR. ADAR promotes lung adenocarcinoma migration and invasion through stabilization of FAK. Sci Signal 2017;10:497.

Kumar P, Dillon L, Shibata Y, Jazaeri A, Jones DR, Dutta A. Extrachromosomal circular DNA is released from normal tissues and cancers into the circulation. Mol Cancer Res 2017;15:1197-205.

Kadota K, Sima CS, Arcila ME, Hedvat C, Kris MG, Jones DR, Adusumilli PS, Travis WD. KRAS mutation is a significant prognostic factor in early-stage lung adenocarcinoma. Am J Surg Pathol 2016;40:1579-90.

Liu Y, Amin EB, Mayo MW, Chudgar NP, Bucciarelli PR, Kadota K, Adusumilli PS, Jones DR. CK2α’ drives lung cancer metastasis by targeting BRMS1 nuclear export and degradation. Cancer Res 2016;76:2675-86.

Liu Y, Mayo MW, Xiao A, Shock LS, Hall EH, Adusumilli PS, Jones DR. Loss of BRMS1 promotes a mesenchymal phenotype through NF-κB-dependent regulation of Twist1.  Mol Cell Biol 2015;35(1):303-17.

Hall EH, Xiao A, Liu Y, Shock L, Brautigan DL, Mayo MW, Adusumilli PS, Jones DR. Breast cancer metastasis suppressor 1 inhibits cell migration and preserves an epithelial phenotype in human lung cells that express oncogenic K-RasV12 and loss of p53. PLoS One 2014 9(4) e95869.

Cieslik M, Stephen SA, Baranova N, Chodaparambil S, Kumar M, Allison D, Xu X, J Jacob Wamsley JJ, Gray LG, Jones DR, Mayo MW, Bekiranov S. Epigenetic coordination of signaling pathways during the epithelial-mesenchymal transition. Epigenet Chromatin 2013;6(1):28.

Kumar M, Allison DF, Baranova NN, Wamsley JJ, Szymura SJ, Katz AJ, Bekiranov S, Jones DR, Mayo MW. NF-B regulates the generation of non-small cell lung cancer initiating cells. PLoS One 2013; 8:e68597.

Liu Y, Mayo MW, Nagji AS, Allred EH, Shock LS, Xiao A, Stelow EB, Jones DR. BRMS1 suppresses lung cancer metastases through a novel E3 ligase function on histone acetyltransferase p300. Cancer Res 2013;73:1308-17.

Allison DF, Wamsley JJ, Kumar M, Li D, Gray LG, Udeshi ND, Hart GW, Jones DR, Hunt DF, Mayo MW. Modification of RelA by O-linked N-Acetylglucosamine links glucose metabolism to NF-B acetylation and transcription. Proc Natl Acad Sci 2012;109:16888-93.

Jones DR, Moskaluk CA, Gillenwater HH, Petroni GR, Burks SG, Philips J, et al. Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small cell lung cancer. J Thorac Oncol 2012;7:1683-90.

Marozkina NV, Wei C, Yemen S, Wallrabe H, Nagji AS, Liu L, Morozkina T, Jones DR, Gaston B. S-nitrosoglutathione reductase in human lung cancer. Am J Resp Cell Mol Biol 2012;46:63-70.

Liu Y, Mayo MW, Nagji AS, Smith PW, Ramsey CS, Li D, Jones DR. Phosphorylation of RelA/p65 promotes DNMT-1 recruitment to chromatin and represses transcription of the tumor metastasis suppressor gene BRMS1. Oncogene 2012;31:1143-54.

Nagji AS, Cho SH, Liu Y, Lee JK, Jones DR. Multi-gene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer. Mol Cancer Ther 2010;9:2834-43.

Nagji AS, Liu Y, Stelow EB, Stukenborg GJ, Jones DR. BRMS1 transcriptional repression correlates with CpG island methylation and advanced pathologic stage in non-small cell lung cancer. J Pathol 2010;221:229-37.

Smith PW, Liu Y, Siefert SA, Petroni GR, Moskaluk CA, Jones DR. Breast Cancer Metastasis Suppressor 1 (BRMS1) suppresses metastasis and correlates with improved patient survival in non-small cell lung cancer. Cancer Letters 2009;276:196-203.

Liu Y, Smith PW, Jones DR. Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing HDAC-1 mediated deacetylation of RelA/p65 and promoting apoptosis. Mol Cell Biol 2006;26:8683-96.